Holen Sie sich die Stockscreener-App
137.01
0.94%
1.24
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$135.77
Offen:
$133.99
24-Stunden-Volumen:
1.86M
Relative Volume:
0.25
Marktkapitalisierung:
$169.96B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
18.64
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
+4.02%
1M Leistung:
+5.56%
6M Leistung:
-9.72%
1J Leistung:
+14.19%
1-Tages-Spanne:
$133.29
$137.12
1-Wochen-Bereich:
$129.02
$137.12
52-Wochen-Spanne:
$108.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
137.07 | 168.35B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,226.27 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
261.13 | 626.09B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
249.07 | 441.94B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
133.66 | 321.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.87 | 293.87B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
FY2026 EPS Estimates for Gilead Sciences Reduced by Analyst - MarketBeat
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today - benzinga.com
MacroGenics stock rises on $10M Gilead option exercise By Investing.com - Investing.com South Africa
MacroGenics stock rises on $10M Gilead option exercise - Investing.com
Gilead Sciences (GILD) EVP converts 6,002 RSUs, with 2,908 shares withheld - Stock Titan
Gilead Sciences Inc. stock outperforms competitors on strong trading day - marketwatch.com
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program - manilatimes.net
Gilead Sciences options activity points to institutional conviction on 2026 upside - Investing.com
Gilead Sciences Target of Unusually High Options Trading (NASDAQ:GILD) - MarketBeat
FY2027 EPS Estimate for Gilead Sciences Lowered by Analyst - MarketBeat
Handelsbanken Fonder AB Has $123.19 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
E. Ohman J or Asset Management AB Has $5.66 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call - The Globe and Mail
Why Gilead Sciences (NASDAQ:GILD) Just Won a Key Drug Development Case? - Kalkine Media
Gilead Sciences: The Market May Be Underestimating Its Growth (Upgrade) (GILD) - Seeking Alpha
Gilead Sciences, Inc. (GILD) Stock Analysis: Exploring a Potential 18.16% Upside with Robust Pipeline and Strategic Collaborations - DirectorsTalk Interviews
Gilead Sciences, Inc. Revenue Breakdown – SIX:GILD - TradingView
Ebola response turns to Merck vaccine, Gilead drug as Congo outbreak worsens - The Spokesman-Review
AB RELATIVE VALUE FUND, INC.'s Gilead Sciences Inc(GILD) Holding History - GuruFocus
Should Gilead’s Swing to a Full‑Year Loss Outlook Require Action From Gilead Sciences (GILD) Investors? - webull.com
Key HIV stat over 70% leaves BofA siding with Gilead - thestreet.com
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results - natlawreview.com
Ebola Response Turns to Merck Vaccine, Gilead Drug as Congo Outbreak Worsens - Bloomberg.com
Czech National Bank Raises Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
PensionDanmark Pensionsforsikringsaktieselskab Purchases 25,515 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
NewEdge Advisors LLC Buys 231,715 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Assenagon Asset Management S.A. Boosts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ: GILD) sets up automatic shelf for wide range of securities - Stock Titan
GILEAD SCIENCES, INC. 2026: Revenue $7.8B, EPS ($8.45) — 10-Q Summary - TradingView
Gilead Sciences: A Strong Quarter Hidden Behind A Bottom-Line Loss (NASDAQ:GILD) - Seeking Alpha
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - marketwatch.com
Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says - Moomoo
Gilead Sciences (NASDAQ:GILD) Given New $123.00 Price Target at Royal Bank Of Canada - MarketBeat
Gilead Sciences Inc Stock (GILD) Moved Down by 3.96% on Aug 5: A Full Analysis - TradingKey
Gilead (GILD) Faces HIV Drug Access Criticism From AIDS Healthcare Foundation - finance.yahoo.com
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch - BioPharma Dive
Leerink Partners Adjusts Price Target on Gilead Sciences to $130 From $126 - Moomoo
Goldman Sachs Adjusts Price Target on Gilead Sciences to $135 From $130 - finance.yahoo.com
Gilead Sciences, Inc. Declares Quarterly Dividend of $0.82 (NASDAQ:GILD) - MarketBeat
The Bull Case For Gilead Sciences (GILD) Could Change Following Deeper 2026 Losses Amid HIV, Oncology Growth - finance.yahoo.com
Gilead Sciences (GILD) Faces Fresh HIV Access Criticism From AIDS Healthcare Foundation - Sahm
Gilead's Steady Long-Term Growth Prospects in HIV and Expansion in Oncology Support a Wide Moat - Morningstar
Gilead Sciences Inc (GILD) (Q2 2026) Earnings Call Highlights: P - GuruFocus
Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock - MarketBeat
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results - Business Wire
Gilead Sciences (GILD) Chairman & CEO Daniel O'Day Sells 15,000 Shares - GuruFocus
Gilead Sciences Q2 Earnings Call Highlights - MarketBeat
Is Gilead Sciences Inc (GILD) Worth the Current Valuation? Q2 Ea - GuruFocus
A Look at Gilead Sciences Inc (GILD) After 3.1% Gain -- GF Value $96.26 vs Price $135.27 - GuruFocus
Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates - finance.yahoo.com
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.37%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):